Global Talent Acquisition Lead - Industrial and Manufacturing Operations

Galderma agrees to buy ZO Skin Health, sources say. Discover more News website advertising Swiss dermatology conglomerate Galderma (GALD.S) has agreed to acquire medical-grade skincare company ZO Skin Health for approximately $1.5 billion, according to two people familiar with the matter. The transaction expands Galderma's footprint in the U.S. physician-distributed skincare market. Strategic financial takeaways. * Valuation Target: The acquisition agreement values ZO Skin Health at approximately $1.5 billion. * Sellers and Advisors: Investment firm Blackstone (BX.N) previously explored a sale through advisors Citigroup (C.N) and Raymond James (RJF.N). * Ownership Structure: Beauty conglomerate L'Oréal (OREP.PA) holds a 20% stake in Galderma. Expanding the U.S. Medical skincare portfolio. Strategic buyers continue to prioritize clinically backed, physician-distributed skincare brands due to steady consumer demand and high barriers to entry compared to over-the-counter alternatives. For Galderma, this acquisition adds a prominent professional-grade portfolio to an existing lineup that includes Cetaphil, Alastin Skincare, Differin Epiduo acne gel, Dysport, and Restylane. Established in 1981, Galderma recently reinforced its regional footprint by opening a U.S. and Latin America headquarters in Miami in August. ZO Skin Health was founded in 2007 by dermatologist Zein Obagi. The brand distributes cleansers, serums, exfoliators, and toners through physicians and licensed skincare professionals. Blackstone (BX.N) acquired the company in 2020 through its tactical opportunities fund. Last month, Reuters reported that Blackstone was evaluating exit options with financial advisers Citigroup and Raymond James. Discover more Freelance journalism platform Learn Engineering Transaction timeline and market response. | Event / Milestone | Details | Key Entities | | Founding of ZO | | Established in 2007 by dermatologist Zein Obagi | ZO Skin Health | | PE Acquisition | | Acquired via tactical opportunities fund in 2020 | Discover more Taste Euro Foods Buy Maps Explore History Business news analysis Investigative journalism courses Journalism ethics training Get Health Tips health | Blackstone (BX.N) | | Sale Exploration | Evaluated sale options with financial advisors | Citigroup (C.N), Raymond James (RJF.N) | | Acquisition Agreement | | Agreed to buy ZO Skin Health for ~$1.5 billion | | Galderma (GALD.S) | The formal announcement of the transaction is expected in the coming days, according to sources familiar with the discussions. Representatives for Galderma and ZO Skin Health did not immediately respond to requests for comment outside regular business hours. Blackstone declined to comment on Tuesday. Discover more News subscription service Digital news archive Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice. More on this Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

Galderma agrees to buy ZO Skin Health for around $1.5 billion, sources say. Published on 10/13/2026 at 07:14 pm EDT - Modified on 10/13/2026 at 07:19 pm EDT NEW YORK, Oct 13 (Reuters) - Swiss skincare conglomerate Galderma has agreed to buy medical-grade skincare company ZO Skin Health for around $1.5 billion, according to two people familiar with the matter. A deal could be announced in the coming days, the people said. ZO and Galderma, which were contacted outside regular business hours, did not immediately respond to requests for comment. ZO's owner, investment firm Blackstone, was exploring a sale of the company with investment banks Citigroup and Raymond James, Reuters reported last month. Blackstone declined to comment on Tuesday. The move by dermatology company Galderma, in which beauty giant L'Oréal owns a 20% stake, will expand its presence in the US market. In August, the company opened a US and Latin America headquarters in Miami. Established in 1981, Galderma also owns skincare brands Cetaphil and Alastin Skincare, Differin Epiduo acne gel, injectable neurotoxin Dysport, and dermal filler brand Restylane. Many strategic buyers are prioritizing clinically backed, physician-distributed skincare brands like ZO because of their efficacy and steadier demand versus over-the-counter products. Dermatologist Zein Obagi founded ZO in 2007. ZO sells skincare products including cleansers, serums, exfoliators and toners that are distributed by physicians and skincare professionals. Blackstone acquired ZO through its tactical opportunities fund in 2020. (Reporting by Abigail Summerville in New York; Editing by Echo Wang in New York and Jamie Freed) By Abigail Summerville (C) Reuters - 2026

Galderma presents new three-year Nemluvio data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older. Published on 10/08/2026 at 07:20 am EDT S&P Capital IQ Galderma announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the ARCADIA trial, Nemluvio achieved deep and lasting skin lesion and itch responses for up to three years. New post-hoc data from the ongoing ARCADIA LTE study showed that adults and adolescents aged =12 years with moderate-to-severe atopic dermatitis who achieved an early clinical response with Nemluvio in the ARCADIA trials, were able to maintain deep and lasting improvements in both skin lesions and itch response through Week 152. The analysis evaluated 295 patients who achieved a clinical response at Week 16 and continued treatment during the maintenance and LTE phases of the study. Deep skin clearance was assessed by the proportion of participants achieving an IGA score of 0 or 1, and those with a more than 90% or 100% improvement from the initial baseline in the EASI score. Among these early responders at one year (Week 56), 77% achieved clear skin or at least a 90% improvement in disease severity. This was maintained up to Week 152, where 76% achieved clear (IGA 0) or almost clear skin (IGA 1), and 80% achieved at least a 90% improvement in disease severity (EASI-90) and 50% achieved complete skin clearance (EASI-100). In addition, at Week 152, 80% achieved an itch-free or nearly itch-free state. Nemluvio was well tolerated, with no new safety signals. The data are consistent with the previously collected safety and efficacy data regarding Nemluvio in adults and adolescents with moderate-to-severe atopic dermatitis. These findings further strengthen the growing body of evidence supporting the long-term efficacy of Nemluvio and its potential to deliver lasting disease control across key symptoms of atopic dermatitis. A separate pre-specified interim analysis of the overall ARCADIA LTE population assessed the long-term safety and efficacy of Nemluvio in 1,903 adults and adolescents aged =12 years with moderate-to-severe atopic dermatitis. At Week 152, Nemluvio was well-tolerated and associated with sustained efficacy, including improvements in skin lesions, itch, sleep disturbance and quality of life. Based on observed case analyses: Up to 91% of patients achieved at least 75% improvement in eczema severity (EASI-75), and up to 75% achieved at least 90% improvement in eczema severity (EASI-90); Up to 67% of patients achieved clear or almost clear skin (IGA 0/1); Up to 88% of patients achieved clinically meaningful itch relief and up to 73% achieved an itch-free or nearly itch-free state; Up to 92% of patients achieved clinically meaningful improvements in dermatology-related quality of life. The safety profile of Nemluvio remained consistent with previous findings through three years of treatment, with no new safety signals identified compared to previous long-term extension study interim analyses. Galderma will also present clinical results from a phase II study designed to assess the pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Results showed that nemolizumab pediatric doses were associated with similar pharmacokinetic exposure compared to adults and adolescents, and were well tolerated and effective in children, with clinically meaningful reductions in skin lesions and itch through Week 16 and sustained up to Week 52. A separate descriptive analysis from the OLYMPIA LTE study showed that Nemluvio also delivered sustained and clinically meaningful improvements across multiple dimensions of prurigo nodularis burden through Week 148, including itch, pain, sleep disturbance, quality of life and overall health status. At Week 48, out of 508 enrolled patients: More than 85% of patients achieved clinically meaningful itch improvement, with about three-quarters of patients achieving an itch-free or nearly itch-free state; 60% reported no prurigo nodularis-associated pain; 85% achieved clinically meaningful improvements in sleep disturbance; 91% experienced clinically meaningful improvements in quality of life; The safety profile of Nemluvio remained consistent with previous findings through three years of treatment, with no new safety signals identified compared to previous long-term extension study interim analyses. Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31? a neuroimmune cytokine that drives itch and is involved in inflammation, epidermal dysregulation and fibrosis in both atopic dermatitis and prurigo nodularis. (C) S&P Capital IQ - 2026